Lilly Korea says KFDA approved Cymbalta, new anti-depressant.
Cymbalta is an SNRI anti-depressant drug, which was approved in the U. S. and Europe in 2004 and 2005, showing a...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
